Drug

Lacosamide

As of the edition of 20 October 2026, Lacosamide is a small molecule: marketed, first approved in 2008 (EU); acts on SCN10A, SCN11A and SCN1A and 7 more; US protection ended in 2026.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status: Marketed; latest approval 2016
Kind: Small molecule
Brand name: Vimpat
First approved: 29 August 2008 (EU)
Approvals on record: 17 in 4 regions
Holder of the most recent approval: Aucta Pharmaceuticals; 5 holders in all
Registered trials: 102, 10 stopped early
Disease areas: Nervous system; Hormones; Mental health; Bones, joints and muscles; Chemically induced; Injuries

US protection

US protection ended in 2026.

The last listed US exclusivity ended in 2026. The application that gives this date is held by UCB.

This is the US only, and it is not the date generics or biosimilars can enter.

The exact date and the listings behind it

In the product

6 listings count towards this date. The exact date and each listing are in the product.

See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.

Targets

Gene	Protein	UniProt
SCN1A	Sodium channel protein type 1 subunit alpha	P35498
SCN4A	Sodium channel protein type 4 subunit alpha	P35499
SCN7A	Sodium channel protein type 7 subunit alpha	Q01118
SCN5A	Sodium channel protein type 5 subunit alpha	Q14524
SCN9A	Sodium channel protein type 9 subunit alpha	Q15858
SCN2A	Sodium channel protein type 2 subunit alpha	Q99250
SCN3A	Sodium channel protein type 3 subunit alpha	Q9NY46
SCN11A	Sodium channel protein type 11 subunit alpha	Q9UI33
SCN8A	Sodium channel protein type 8 subunit alpha	Q9UQD0
SCN10A	Sodium channel protein type 10 subunit alpha	Q9Y5Y9

Gene

Protein

UniProt

SCN1A

Sodium channel protein type 1 subunit alpha

P35498

SCN4A

Sodium channel protein type 4 subunit alpha

P35499

SCN7A

Sodium channel protein type 7 subunit alpha

Q01118